Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study

Findings from a phase II study demonstrates that the combination of irinotecan with trifluridine/tipiracil and #Bevacizumab shows promising efficacy and tolerable safety as second-line therapy in metastatic #ColorectalCancer. #Medsky
#STTT #OpenAccess: doi.org/10.1038/s413...

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

XB2001 combined with trifluridine/tipiracil ± #Bevacizumab shows a favorable safety profile and promising early efficacy in refractory metastatic #ColorectalCancer, highlighting IL-1α inhibition as a potential therapeutic strategy.

#STTT #OpenAccess: doi.org/10.1038/s413...

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

This phase 2/3 #ClinicalTrial demonstrates that combining #Finotonlimab with #Bevacizumab significantly improves clinical outcomes for advanced #HepatocellularCarcinoma, providing a high-efficacy first-line therapeutic strategy.

#STTT #OpenAccess: doi.org/10.1038/s413...

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial - Nature Communications Recently, the dose escalation stage of the GLORIA trial investigating NOX-A12 (L-RNA aptamer-based CXCL12 inhibitor) in combination with radiotherapy in patients with glioblastoma was reported. Here, ...

Tumor revascularization in #glioblatoma is driven by 2 spatially distinct pathways. The GLORIA trial investigated a novel first-line approach for #glioblastoma patients with unfavorable prognostic features: #radiotherapy + #LRNAaptamer targeting #CXCL12 + #bevacizumab

www.nature.com/articles/s41...

Alternating modified CAPOX/CAPIRI plus bevacizumab shows promising activity in untreated unresectable metastatic colorectal cancer in a phase 2 trial.
Advancing first-line combination strategies.
doi.org/10.1038/s413...
#MetastaticColorectalCancer #CAPOX #CAPIRI #Bevacizumab #Phase2Trial

🎨Science Visuals | 🎯Targeted therapies are transforming treatment for #ColorectalCancer (#CRC)
🔸Key approaches include #EGFR inhibitors like #Cetuximab & #Panitumumab and #VEGF inhibition with #Bevacizumab.
🚫#Tumor growth and #angiogenesis.
#Cancer #CancerResearch #Oncology

HCC Subgroups May Guide Personalized Treatment, Patient Selection | Docwire News Machine learning-identified subgroups of patients with unresectable HCC treated with atezo-bev may help guide personalized treatment strategies and patient selection.

Researchers used machine learning to identify subgroups of patients with unresectable #HepatocellularCarcinoma treated with #atezolizumab and #bevacizumab with different patterns of progression and prognostic trajectories.
#HCC #hepatology #oncology

#RNAprofiling adds clinical value in cancer therapy: ≥6 altered genes link to shorter survival, while #TP53 mutations correlate with #VEGFA overexpression, suggesting possible #bevacizumab sensitivity. @mdanderson.bsky.social

#OpenAccess in #STTT: doi.org/10.1038/s413...

Alternating modified CAPOX/CAPIRI plus bevacizumab shows promising activity in untreated unresectable metastatic colorectal cancer in a phase 2 trial.
Advancing first-line combination strategies.
doi.org/10.1038/s413...
#MetastaticColorectalCancer #CAPOX #CAPIRI #Bevacizumab #ClinicalOncology

This #SystematicReview and Meta-analysis compared efficacy and safety of combining #bevacizumab with re-irradiation versus bevacizumab alone in recurrent high-grade #glioma:
journals.sagepub.com/doi/full/10....

Phase 2 trial shows that combining #TACE with #atezolizumab and #bevacizumab is feasible and safe for intermediate-stage #HCC, achieving high response rates and encouraging survival outcomes with manageable toxicity.

#OpenAccess in #STTT: doi.org/10.1038/s413...

AGO-OVAR 2.29 / ENGOT-ov34: Atezolizumab Added to Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - OncoDaily AGO-OVAR 2.29 shows atezolizumab added to bevacizumab and non-platinum chemotherapy does not significantly improve OS or PFS in recurrent ovarian cancer.

AGO-OVAR 2.29 / ENGOT-ov34: Atezolizumab Added to Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Atezolizumab #Bevacizumab #OvarianCancer

Atezo-Bev Shows Real-World Efficacy in Unresectable HCC Outcomes of a retrospective study of atezolizumab plus bevacizumab for unresectable HCC were similar to those of the IMbrave150 study.

#Atezolizumab plus #Bevacizumab (atezo-bev) has shown favorable efficacy and manageable toxicity in patients with unresectable #HepatocellularCarcinoma (HCC). Study in Biomedicines.

Read here: https://bit.ly/3MRWJDW

#RareDisease #AtezoBev #HCC #Oncology

Baseline CD28⁻CD57⁺CD8⁺ T Cells Predict Early Response in HCC Baseline CD28-CD57+CD8+ T-cell levels may help identify patients with HCC unlikely to respond early to atezolizumab plus bevacizumab.

A simple blood test measuring CD28–CD57+CD8+ T cells at baseline may help identify which patients with #HepatocellularCarcinoma (HCC) are less likely to respond early to #Atezolizumab plus #Bevacizumab. Study in Scientific Reports.

Learn more: https://bit.ly/3MntBEC

#RareDisease #MedSky #HCC

Atezolizumab + Bevacizumab in MSI-Like Colorectal Cancer: Who Truly Benefits? - OncoDaily Atezolizumab + bevacizumab shows high response in MSI-like colorectal cancer but limited benefit in MSS MSI-like tumors, highlighting biomarker limitations and microenvironment barriers.

Atezolizumab + Bevacizumab in MSI-Like Colorectal Cancer: Who Truly Benefits?

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Atezolizumab #Bevacizumab #ColorectalCancer #CRC

First clinical results of XB2001, an IL-1α–targeting #antibody, show promising efficacy and safety in #chemoresistant #mCRC when combined with FTD/TPI and #bevacizumab, demonstrating improved PFS and reduced IL-6 levels. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

BioDlink Successfully Ships Bevacizumab to Colombia, Paving Way for Cancer Treatment Access BioDlink's first international shipment of Bevacizumab injection to Colombia marks a significant advancement in targeted cancer therapy.

BioDlink Successfully Ships Bevacizumab to Colombia, Paving Way for Cancer Treatment Access #Colombia #Kexing_Biopharm #BioDlink #Bevacizumab

🌟 Discover #Avastin ( #Bevacizumab): Targeting Tumor Blood Supply!

❓ How does it block #VEGF and stop tumor growth?
⚡ Key therapy for #mCRC & #NSCLC.
💊 Trusted worldwide for cancer care.

🔗 Learn more: dengyuemed.com/product/avas...

#HongKongDrugWholesaleDistributor
#HongKongDengYueMedicine

Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial

This phase 2 trial demonstrates that combining #TACE with atezolizumab & #bevacizumab is safe and feasible for intermediate-stage #HCC, showing promising efficacy and underscoring the potential of this synergistic triple regimen. #medsky

#OpenAccess #STTT: doi.org/10.1038/s413...

▼Bevacizumab gamma (LYTENAVA) bei feuchter Makuladegeneration (Langversion) Bevacizumab ist nun „on label“ als Bevacizumab gamma bei feuchter Makuladegeneration im Handel. Die Zulassung stützt sich stark auf Daten der off-label-Anwendung.

#Bevacizumab gamma (LYTENAVA) bei feuchter #Makuladegeneration (Langversion)

Bevacizumab ist nun „on label“ als Bevacizumab gamma bei feuchter Makuladegeneration im Handel. Die Zulassung stützt sich stark auf Daten mit off-label-Bevacizumab.
www.arznei-telegramm.de/html/2025_08...

BioDlink Secures Authorization for Bevacizumab Launch in Indonesia, Continuing Global Expansion BioDlink's Bevacizumab Injection has been approved in Indonesia, marking a significant step in their global expansion and enhancing patient access to vital treatments.

BioDlink Secures Authorization for Bevacizumab Launch in Indonesia, Continuing Global Expansion #Indonesia #Jakarta #BioDlink #Bevacizumab

XB2001, combined with FTD/TPI and #bevacizumab, demonstrated a favourable safety profile and promising efficacy in the third-line treatment of #mCRC, underscoring its biological and clinical relevance. #medsky

#STTT #OpenAccess: www.nature.com/articles/s41...

BioDlink's Bevacizumab Launch in Colombia and Pakistan Marks New Era in Oncology Treatments BioDlink accelerates its global growth with successful bevacizumab launches in Colombia and Pakistan, striving to enhance oncology treatment access.

BioDlink's Bevacizumab Launch in Colombia and Pakistan Marks New Era in Oncology Treatments #China #Suzhou #Kexing_Biopharm #BioDlink #Bevacizumab

Markey researchers identify genetic marker that could guide brain cancer treatment

UK Markey researchers found that CDK4 amplification may predict who benefits most from bevacizumab, a common brain cancer drug. This work could help personalize treatment and improve outcomes.
#Glioblastoma #Bevacizumab #PrecisionMedicine

BioDlink's Bevacizumab Gains Nigeria Approval, Enhancing Global Reach in Healthcare BioDlink's Bevacizumab Injection has received marketing authorization in Nigeria, boosting its global footprint. The approval addresses urgent healthcare needs in Africa.

BioDlink's Bevacizumab Gains Nigeria Approval, Enhancing Global Reach in Healthcare #None #Nigeria #BioDlink #Bevacizumab

Yvonne Diaz: Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - OncoDaily Nature Communications

Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - Yvonne Diaz
@yvonnediaz.bsky.social

oncodaily.com/science/beva...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ALK #Alectinib #Bevacizumab

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer - OncoDaily Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer / ASCO GI, Bevacizumab, BRAF

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
@skopetz.bsky.social
@fda.gov

oncodaily.com/insight/meta...

#ASCOGI #Bevacizumab #Cancer #ColorectalCancer #EncorafenibCetiximab #FDA #OncoDaily #Oncology #Pfizer #CRC

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma This multicenter retrospective cohort study identified key risk factors for variceal bleeding (VB) in 640 patients with advanced hepatocellular carcinoma receiving atezolizumab–bevacizumab. Main port...

Interesting work looking at risk factors for variceal bleeding in #HCC Patients on #atezolizumab #bevacizumab
Confirms that main PVT is a major risk factor with was shown in IM-BRAVE 150. The other risk factors identified are self evident
#liversky

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft sa...

#atezolizumab plus #bevacizumab prior #liver #transplantation for #HCC - JHEP Reports www.jhep-reports.eu/article/S258...
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!

Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMD - Eyewire+ The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the tr

#OutlookTherapeutics #NICERecommendation #Lytenava #bevacizumabgamma #bevacizumab #WetAMD #ophthalmology #biopharmaceuticals #retinadisease #NICE #NICErecommended #VEGF #WetAMDpatients #NHSEngland #NHSWales #MHRA #NORSEONE #NORSETWO #NORSETHREE #clinicaltrials #Cencora
eyewire.news/news/outlook...